AltPep develops early disease-modifying treatments and detection tools for amyloid diseases.

Our lead programs aim to identify Alzheimer’s disease and Parkinson’s disease long before symptoms occur and then neutralize toxic soluble oligomers associated with these diseases.

Our Platform

The AltPep™ Platform is based on a collection of de novo designed synthetic peptides. The growing library is an arsenal that specifically targets the root causes of disease at the molecular level.

SOBA™ Diagnostics

For the early detection and tracking of amyloid diseases using plasma and CSF.

SOBIN™ Therapeutics

These peptides target and neutralize the toxic soluble oligomers associated with amyloid diseases.

Recent News and Publications

Promising data from large Alzheimer’s study bodes well for this Seattle startup

"Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data suggest that the treatment, called lecanemab, eases cognitive decline. The findings also rejuvenated hope in a therapeutic approach targeting peptides that form nasty clumps in the brain of people with Alzheimer’s. The news bodes well for companies like Seattle’s AltPep that are taking a similar path toward detecting and treating...

Seattle startup aiming to detect, treat Alzheimer’s and Parkinson’s disease raises cash

"The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke with GeekWire about AltPep’s progress on its experimental blood test to detect Alzheimer’s disease at the earliest stages. "We’re going after that first molecular trigger for the pathology,” said Daggett, who is also a UW professor of bioengineering. The 3-year old startup is also developing a diagnostic for...

Review: Amyloid-β Oligomers: Multiple Moving Targets

“Alzheimer’s Disease (AD) is a neurodegenerative disorder that is characterized clinically by progressive cognitive decline and pathologically by the β-sheet rich fibril plaque deposition of the amyloid-β (Aβ) peptide in the brain. While plaques are a hallmark of AD, plaque burden is not correlated with cognitive impairment. Instead, Aβ oligomers formed during the aggregation process represent the main agents of neurotoxicity, which occurs 10–20 years before patients begin to show symptoms…”

AltPep Receives FDA Breakthrough Device Designation for SOBA-AD, A Simple Blood Test for the Detection of Alzheimer’s Disease

Breakthrough designation reinforces the significant potential of SOBA-AD assay to address the unmet need in Alzheimer’s Disease (AD) detection SOBA-AD assay is designed to selectively detect toxic oligomers that trigger a cascade of events associated with AD, including cognitive impairment and neurodegeneration SEATTLE, WA – March 1, 2022 – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the U.S....

AltPep Appoints Nancy Hill to Newly Created Position of Chief Product Officer

SEATTLE, WA – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product Officer. In this role, Nancy is responsible for product development and commercialization of AltPep’s pipeline. “We are thrilled to welcome Nancy to AltPep as we focus on advancing our products through development,” said Valerie Daggett, Ph.D.,...